Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis & Investment Frameworks
Vertex Pharmaceuticals Incorporated (VRTX) stock analysis on Invetso. Review Vertex Pharmaceuticals Incorporated’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Vertex Pharmaceuticals Incorporated Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Vertex Pharmaceuticals Incorporated Key Financial Metrics
- Market Cap: $130.44B
- Revenue: $12.07B
- P/E Ratio: 32.99
- ROE: 23.31%
- ROIC: 17.33%
- Dividend Yield: N/A
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated Investment Frameworks
Invetso analyzes Vertex Pharmaceuticals Incorporated (VRTX) across the following frameworks:
- Vertex Pharmaceuticals Incorporated 10Y Growth Potential
- Vertex Pharmaceuticals Incorporated Scenario Analysis
- Vertex Pharmaceuticals Incorporated Risks & Opportunities
- Vertex Pharmaceuticals Incorporated Economic Moat
- Vertex Pharmaceuticals Incorporated Business Model
- Vertex Pharmaceuticals Incorporated Management
- Vertex Pharmaceuticals Incorporated SWOT Analysis
- Vertex Pharmaceuticals Incorporated Porter's 5 Forces
- Vertex Pharmaceuticals Incorporated PESTLE Analysis
- Vertex Pharmaceuticals Incorporated ESG Analysis